A plant-derived oral drug is thought to stop multiple sclerosis progression. This breakthrough could be a step forward in preventing and treating multiple sclerosis and other autoimmune diseases.
The drug treatment, called T20K, was extracted from a traditional medicinal plant, called the Oldenlandia affinis and has been successful in an animal model.
“This is a really exciting discovery because it may offer a whole new quality of life for people with this debilitating disease,” says Dr. Gruber, a researcher from University of Queenland.
“Cyclotides are present in a range of common plants, and they show significant potential for the treatment of auto immune diseases,” he said.
“The T20K peptides exhibit extraordinary stability and chemical features that are ideally what you want in an oral drug candidate.”
According to Medical Xpress, MedUni Vienna with Freiburg University Hospital has filed patent applications in several countries and licensed them out to Cyxone for further development. A Phase I clinical trial for this could start at the end of 2018.
Do you feel hopeful about this plant-based multiple sclerosis drug?
Did you read all our Real People with MS interviews?